48,469
edits
Difference between revisions of "Lymphangioleiomyomatosis"
Jump to navigation
Jump to search
→See also
| (3 intermediate revisions by the same user not shown) | |||
| Line 18: | Line 18: | ||
| Assdx = | | Assdx = | ||
| Syndromes = [[tuberous sclerosis]] | | Syndromes = [[tuberous sclerosis]] | ||
| Clinicalhx = almost always women of childbearing age, recurrent pneumothorax | | Clinicalhx = almost always women of childbearing age, recurrent [[pneumothorax]] | ||
| Signs = | | Signs = | ||
| Symptoms = dyspnea | | Symptoms = dyspnea | ||
| Line 35: | Line 35: | ||
==General== | ==General== | ||
*Clinical: [[dyspnea]], recurrent pneumothorax. | *Clinical: [[dyspnea]], recurrent [[pneumothorax]]. | ||
*May be an indication for lung transplantation. | *May be an indication for lung transplantation. | ||
*Non-neoplastic muscle proliferation versus tumour that can metastasize.<ref name=pmid20235883>{{Cite journal | last1 = Taveira-DaSilva | first1 = AM. | last2 = Pacheco-Rodriguez | first2 = G. | last3 = Moss | first3 = J. | title = The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. | journal = Lymphat Res Biol | volume = 8 | issue = 1 | pages = 9-19 | month = Mar | year = 2010 | doi = 10.1089/lrb.2009.0024 | PMID = 20235883 }}</ref> | *Non-neoplastic muscle proliferation versus tumour that can metastasize.<ref name=pmid20235883>{{Cite journal | last1 = Taveira-DaSilva | first1 = AM. | last2 = Pacheco-Rodriguez | first2 = G. | last3 = Moss | first3 = J. | title = The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. | journal = Lymphat Res Biol | volume = 8 | issue = 1 | pages = 9-19 | month = Mar | year = 2010 | doi = 10.1089/lrb.2009.0024 | PMID = 20235883 }}</ref> | ||
**It has been hypothesized that LAM represent a non-malignant [[metastasis]] of a renal [[angiomyolipoma]].<ref name=pmid17003820/> | |||
Notes: | Notes: | ||
| Line 59: | Line 60: | ||
*Associated with [[angiomyolipoma]]s. | *Associated with [[angiomyolipoma]]s. | ||
**Seen in ~30% of sporadic cases, and in ~90% of cases with tuberous sclerosis.<ref name=pmid17003820/> | **Seen in ~30% of sporadic cases, and in ~90% of cases with tuberous sclerosis.<ref name=pmid17003820/> | ||
*Associated with [[tuberous sclerosis]] | *Associated with [[tuberous sclerosis]] - esp. TSC2 mutations. | ||
**In the context of [[tuberous sclerosis]], [[angiomyolipoma]] of the kidney often preceeds LAM.<ref name=pmid17003820>{{cite journal |author=Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA |title=Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors |journal=Kidney Int. |volume=70 |issue=10 |pages=1777–82 |year=2006 |month=November |pmid=17003820 |doi=10.1038/sj.ki.5001853 |url=}}</ref> | **In the context of [[tuberous sclerosis]], [[angiomyolipoma]] of the kidney often preceeds LAM.<ref name=pmid17003820>{{cite journal |author=Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA |title=Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors |journal=Kidney Int. |volume=70 |issue=10 |pages=1777–82 |year=2006 |month=November |pmid=17003820 |doi=10.1038/sj.ki.5001853 |url=}}</ref> | ||
| Line 97: | Line 98: | ||
*[[Medical lung diseases]]. | *[[Medical lung diseases]]. | ||
*[[PEComa]]. | *[[PEComa]]. | ||
*[[Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis]]. | |||
==References== | ==References== | ||